Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...

“Comirnaty contains messenger RNA (mRNA), a kind of genetic material. The mRNA is used by the body to make a mimic of one of the proteins in the virus that causes COVID-19.

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

Pfizer PFE COVID revenues have been declining due to lower demand. The company records direct sales and alliance revenues ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Pfizer also provides medicines and vaccines in various therapeutic areas, such as: Pneumococcal disease, meningococcal ...

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

Amid a share value slump and executive turmoil, Pfizer reported a robust quarter, thanks in part to Covid-19 drug sales.

Please report side effects. See the full CMI for further details. 1. Why am I being given COMIRNATY JN.1? COMIRNATY JN.1 is a vaccine given to prevent coronavirus disease 2019 (COVID-19 ...